2 hours HC Wainwright Reaffirms Buy Rating for Legend Biotech (NASDAQ:LEGN) MarketBeat
HC Wainwright reaffirmed a “buy” rating and set a $73.00 price target on shares of Legend Biotech in a report on Monday.
HC Wainwright reaffirmed a “buy” rating and set a $73.00 price target on shares of Legend Biotech in a report on Monday.